Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

Inclusion Criteria:

• ≥18 years of age.

• Newly diagnosed multiple myeloma.

• Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1.

• Women of childbearing potential must have a negative serum pregnancy test prior tostarting treatment and agree to use a highly effective method of contraception, suchas a hormonal method that inhibits ovulation, an intrauterine device, or a vasectomypartner.

• Males: agree to use a highly effective contraceptive method, such as a male condomor vasectomy.

Exclusion Criteria:

• History of previous treatment for MM.

• Active central nervous system (CNS) involvement or clinical signs of meningealinvolvement of multiple myeloma.

• Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes)or AL amyloidosis.

• Severe active infection secondary to viruses, bacteria or fungi.

• Pulmonary disease requiring supplemental oxygen.

• History of allogeneic or autologous hematopoietic cell transplantation.

• Vaccination with live attenuated virus in the 4 weeks prior to teclistamabadministration.

• Major surgery during the 2 weeks prior to the first dose or absence of completerecovery from surgery.

• Presence of other concomitant malignancy.

• Hepatitis B and C virus infection or human immunodeficiency virus (HIV) infection.

• Cerebrovascular events or seizures in the last 6 months.

• Congestive heart failure class III-IV according to NYHA (New York Heart AssociationStage).

• Acute myocardial infarction or history of coronary revascularization surgery in thelast 6 months.

• Women of childbearing age: active pregnancy prior to the first administration oftreatment.